biotech weekly analysis
Auvelity FDA Approval Launches the First Non-Antipsychotic Market for Alzheimer Agitation
Roughly 39 million people live with HIV. Most of them are on treatment. A large proportion of those people are aging, developing comorbidities, accumulating drug resistance, and managing the complexity of multi-tablet regimens that have kept the virus suppressed but come with their own set of problems. Gilead Sciences has a drug in FDA review…
What the FDA’s Mixed Regulatory Signals in 2026 Mean for Smaller Biotechs
The FDA did not produce a landmark approval this week. What it produced was something arguably more useful for investors watching the sector: a clear picture of where the regulatory environment is heading and what that means for the companies positioned inside it. A June 30 PDUFA date for a second major indication from one…
Datroway TNBC Approval and the ADC Platform Sweep That Is Reshaping Oncology
The FDA had a productive week. Two ADC approvals from the same partnership in two weeks. A Phase 3 trial in a rare skeletal disorder with no approved treatment. A Breakthrough Therapy Designation in a market already served by two blockbusters. And the first oral drug approved to prevent COVID-19 after exposure. None of these…
